Authors

Latest:

Dr Stadler on Enhancing Diversity in Early Phase Clinical Trials For Underserved Communities

Walter M. Stadler, MD, discusses his role within the Stand Up To Cancer® 4-team initiative, where he will aim to enhance diversity in early-phase clinical trials in underserved urban community.

Walter Rayford, MD, PhD, MBA

Latest:

Dr. Rayford on the Racial Genomics of Prostate Cancer

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.

Walter Stadler, MD, University of Chicago

Warner K. Huh, MD, UAB

Latest:

Cervical Cancer Management: Looking Toward the Future of Care

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.

Wassim Abida, MD, PhD

Latest:

Dr. Abida on Future Research Directions in mCRPC

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Waun K. Hong, MD

Latest:

Dr. Hong on Advances in Head and Neck Cancer

Waun K. Hong, MD, FACP, DMSc, division head, American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and 2018 Giant of Cancer Care® in Head and Neck Cancer, discusses advances in the treatment of patients with head and neck cancer.

Wayne A. Bardwell, PhD, MBA

Latest:

Dr. Bardwell Expresses the Importance of Listening

Dr. Wayne Bardwell from UCSD Cancer Center Expresses the Importance of Listening

Wayne A. Marasco, MD, PhD

Latest:

Dr. Marasco on Engineering CAR T Cells

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

Wayne Kuznar

Latest:

Lenalidomide/Rituximab Regimens Show Encouraging Responses in Relapsed/Refractory Follicular Lymphoma, But Slow Accrual Axes Study

The regimen of lenalidomide in combination with rituximab with bendamustine are effective therapies for relapsed/refractory follicular lymphoma, with high rates of overall and complete metabolic response by PET, according to data from the randomized phase 2 HOVON110/Rebel trial.

Wei Z. Ai, MD

Latest:

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Weijing Sun, MD

Latest:

Dr. Sun on the KEYNOTE-062 Design in Advanced Gastric/GEJ Cancer

Weijing Sun, MD, FACP, discusses the design of the KEYNOTE-062 trial in advanced gastric/gastroesophageal junction cancer.

Weiyun Z. Ai, MD, PhD

Latest:

Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced CTCL

Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma.

Welela Tereffe, MD

Latest:

Dr. Tereffe on Treatment After Neoadjuvant Chemotherapy in Breast Cancer

Welela Tereffe, MD, associate professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the role of radiation therapy in the treatment of patients with breast cancer who previously received neoadjuvant chemotherapy.

Wells A. Messersmith, MD

Latest:

Dr. Messersmith on the Potential for Trastuzumab Deruxtecan in HER2+ CRC

Wells Messersmith, MD, discusses the potential for fam-trastuzumab deruxtecan-nxki as a treatment for patients with HER2-positive colorectal cancer.

Wells A. Messersmith, MD, FACP, University of Colorado Cancer Center

Wendy A. Woodward, MD, PhD

Latest:

New Frontier for Genomics: Radiotherapy in Early Breast Cancer

By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.

Wendy Setiawan, PhD

Latest:

Wendy Setiawan on Pancreatic Cancer Incidence Across Ethnic Populations

Wendy Setiawan, PhD, assistant professor of Preventive Medicine, Department of Preventive Medicine, Keck School of Medicine of University of Southern California, discusses a study that examined differences in pancreatic cancer incidence across five racial/ethnic populations in a multiethnic cohort.

Whitney S. Graybill, MD, MS

Latest:

Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study

Whitney S. Graybill, MD, MS, presents data from an analysis of the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in patients with advanced ovarian cancer.

Will Lowrance, MD, MPH

Latest:

Chronic Kidney Disease Associated With Increased Risk of Renal and Urothelial Cancers

Does renal disease increase one's risk of developing cancer?

Will Pass, DVM

Latest:

Oncologists Play Many Roles in Lung Cancer Screening Programs

The role of the oncologist is essential to the design, operation, development and associate research of lung cancer screening programs.